Press releaseGlobe Newswire
Eikon Therapeutics
EIKN · NASDAQ
$8.18+$0.48 (+6.23%)TodayMarket closed ·
Prev close $7.70
Latest news
- Press releaseGlobe Newswire
Eikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate Cancer
- NewsTim Melvin
Alpha Buying: Follow the Money From NVIDIA and Merck
- Press releaseGlobe Newswire
Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer
- Press releaseGlobe Newswire
Eikon Therapeutics to Participate in Investor Conferences in September 2026
- Press releaseGlobe Newswire
Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald
- Press releaseGlobe Newswire
Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
- Press releaseGlobe Newswire
Eikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma
- Press releaseGlobe Newswire
Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to its Scientific Advisory Board
- NewsAvi Kapoor
Crude Oil Falls Sharply; US Durable Goods Orders Increase 0.3% In June
- NewsAvi Kapoor
Baker Hughes Posts Upbeat Q2 Earnings, Joins Forte Biosciences, Eikon Therapeutics And Other Big Stocks Moving Higher On Monday
- Press releaseGlobe Newswire
Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- NewsAvi Kapoor
Zebra Technologies, Vishay Precision Group, Quantum Computing, Aramark And Other Big Stocks Moving Higher On Tuesday
- NewsAvi Kapoor
Domino's Posts Downbeat Q1 Results, Joins Real Brokerage And Other Big Stocks Moving Lower In Monday's Pre-Market Session
- NewsNamrata Sen
Wall Street Braces For IPO Boom: Goldman Says 2026 Listings Could Hit $160 Billion As Tech, AI Lead
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.